Patents Assigned to SmithKline Beecham p.l.c.
  • Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
    Publication number: 20040110800
    Abstract: A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
    Type: Application
    Filed: December 2, 2003
    Publication date: June 10, 2004
    Applicant: SmithKline Beecham p.l.c. & SmithKline Beecham Laboratoires Pharmaceutiques
    Inventors: Antoine Michel Alain Bril, Robin Edwin Buckingham, Nassirah Khandoudi
  • Piperazine derivatives as 5-HT1B antagonists
    Patent number: 6747030
    Abstract: Piperazine derivatives of formula(1), processes for their preparation, pharmaceutical compositions containing them in the treatment of CNS and other disorders and in their use in therapy as 5-HT1B antagonists are disclosed herein.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: June 8, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Howard Marshall, Mervyn Thompson, Paul Adrian Wyman
  • Treatment of diabetes with rosiglitazone and insulin
    Publication number: 20040106543
    Abstract: A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of Compound (I) and insulin to a mammal in need thereof.
    Type: Application
    Filed: November 25, 2003
    Publication date: June 3, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Stephen Alistair Smith
  • Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
    Publication number: 20040097553
    Abstract: A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, characterized in that it: (i) comprises water in the range of from 0.2 to 1.1% w/w; and (ii) provides an infrared spectrum containing peaks at 764 and 579 cm−1; and/or (iii) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in FIG. II; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.
    Type: Application
    Filed: October 24, 2003
    Publication date: May 20, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Michael John Sasse, Paul David James Blackler, David C. Lee
  • Treatment of diabetes with thiazolidinedione and sulphonylurea
    Publication number: 20040097556
    Abstract: A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and an insulin secretagogue, to a mammal in need thereof.
    Type: Application
    Filed: November 10, 2003
    Publication date: May 20, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Stephen Alistair Smith
  • Novel composition and use
    Publication number: 20040091531
    Abstract: A pharmaceutical composition which composition comprises an insulin sensitiser and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of the insulin sensitiser and the use of such composition in medicine.
    Type: Application
    Filed: November 5, 2003
    Publication date: May 13, 2004
    Applicants: SmithKline Beecham p.l.c., SmithKline Beecham Corporation
    Inventors: Robert Glinecke, Susan Marie Milosovich, William Muldoon, Vincenzo Re, Joseph Sauer, Janet Louise Skinner
  • Nitro-benzamide useful as anti-arrhythmic agent
    Publication number: 20040092771
    Abstract: Hydrated N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride characterised in that it: (i) comprises water in the range of from 1.7 to 2.4 molar equivalents; and/or (ii) has a melting point above 145° C. and/or, (iii) provides an infra red spectrum containing peaks at 3510, 3342, 3076, 1665, 1598, 1343, 1330, 1216 and 801 cm−1; and/or (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as represented in Table I; and/or (v) provides an X-ray powder refraction (XRPD) pattern substantially as represented in Table II; a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.
    Type: Application
    Filed: December 2, 2003
    Publication date: May 13, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Graham Ralph Slater, Paul Jeffrey Westlake
  • Methods of modulating FabH activity
    Publication number: 20040087506
    Abstract: The invention provides FabH polypeptides and polynucleotides encoding FabH polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing FabH polypeptides to screen for antibacterial compounds.
    Type: Application
    Filed: September 23, 2003
    Publication date: May 6, 2004
    Applicants: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Alexaxndros K. Konstantinidis, John Timothy Lonsdale, Glen Scott Van Aller
  • Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
    Publication number: 20040081697
    Abstract: A pharmaceutical composition, which composition comprises: an insulin sensitiser and another antidiabetic agent and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of at least one of the insulin sensitiser and the other antidiabetes agent, and the use of such composition in medicine.
    Type: Application
    Filed: October 21, 2003
    Publication date: April 29, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Karen Lewis, Nicola Jayne Lilliott, Donald Colin MacKenzie, Vincenzo Re
  • Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
    Publication number: 20040082621
    Abstract: A pharmaceutical composition comprising Compound (I), characterised in that the composition comprises 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.
    Type: Application
    Filed: November 19, 2003
    Publication date: April 29, 2004
    Applicants: SmithKline Beecham p.l.c., SmithKline Beecham Corporation
    Inventors: Jeffrey Roger Granett, Hamish Ross, Jaikrishna Patel, Robin Kevin John Price, Paul Nigel Wray
  • Novel process
    Publication number: 20040081960
    Abstract: Novel bacterial genes, microorganisms and processes for improving the manufacture of 5R clavams, eg. clavulanic acid.
    Type: Application
    Filed: February 24, 2003
    Publication date: April 29, 2004
    Applicants: SmithKline Beecham p.l.c., The Governors of the University of Alberta
    Inventors: Cecilia Anders, Barry Barton, John Patrick Griffin, Susan Jensen, Roy Henry Mosher, Ashish Sudhakar Paradkar
  • Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
    Publication number: 20040082041
    Abstract: 1
    Type: Application
    Filed: November 24, 2003
    Publication date: April 29, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Richard Mark Hindley, Stefan Roland Woroniecki
  • Pharmaceutical formulation
    Patent number: 6726908
    Abstract: This invention relates to pharmaceutical formulations comprising amoxycillin and a salt clavulanic acid in a ratio of 14:1.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: April 27, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventor: Daniel Joseph Burch
  • Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23
    Publication number: 20040077727
    Abstract: A compound of formula (I) wherein: R is isopropyl; n is 0; R1 is naphthylmethyl; R2 is t-butyl; and R3 is methyl; is useful in the treatment of disorders mediated by s-CD23.
    Type: Application
    Filed: October 3, 2003
    Publication date: April 22, 2004
    Applicant: SmithKline Beecham P.L.C.
    Inventors: John Gerard Ward, Andrew Faller
  • Use of nitric oxide synthase inhibitors for the treatment of diabetes
    Publication number: 20040072905
    Abstract: A method for the treatment and/or prophylaxis of Type II diabetes, which method comprises the administration, to a human or non-human mammal, of an effective non-toxic pharmaceutically acceptable amount of an NO synthase inhibitor, such as aminoguanidine, or a pharmaceutically acceptable derivative thereof.
    Type: Application
    Filed: July 24, 2003
    Publication date: April 15, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Nicholas Charles Turner, Valerie Piercy
  • Liquid oral compositions comprising a calcium compound and an acidulant
    Patent number: 6719963
    Abstract: Acidic oral compositions having reduced tooth erosion characteristics, especially acid beverages such as fruit juice drink concentrates, or oral healthcare products such as mouthwashes, are prepared by adding a calcium compound to the acid composition so that the mol ratio of calcium to acid ranges from 0.3 to 0.8, and the pH of the composition, if necessary after adjustment with an alkali, is from 3.5 to 4.5.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: April 13, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventor: David Myatt Parker
  • Process for making paroxetine
    Patent number: 6716985
    Abstract: Compounds of structure (1) are obtained by reduction of compounds of the structures: Compounds of structure (1), especially where Z is a hydrogen atom or a 3,4-methylenedioxyphenyl group, are important intermediates for inter alia paroxetine.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: April 6, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Victor Withold Jacewicz, Marvin Sungwhan Yu, Evgeny Shapiro
  • Use of leptin antagonists for the treatment of diabetes
    Publication number: 20040048773
    Abstract: The use of an antagonist of leptin for the manufacture of a medicament for the treamtne tof disorders resulting from deficiencies in insulin secretion, hyperglycaemia and insulin resistance.
    Type: Application
    Filed: October 17, 2002
    Publication date: March 11, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Michael Cawthorne, Valur Emilsson, Yong-Ling Liu
  • Peptide-based gemini compounds
    Publication number: 20040043939
    Abstract: New peptide-based gemini compounds comprising two linked chains: 1
    Type: Application
    Filed: August 25, 2003
    Publication date: March 4, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Patrick Camilleri, Andreas Kremer, Simon Quentyn John Rice
  • Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
    Patent number: 6699879
    Abstract: The present invention provides phenyl urea and phenyl thiourea derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors, of formula (I) in which: Z represents oxygen or sulfur; and R1 to R7 represent various substituent groups; and pharmaceutically acceptable salts thereof. In particular, these compounds are of potential use in the treatment of obesity including obesity observed in Type 2(non-insulin-dependent) diabetes patients and/or sleep disorders.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: March 2, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Coulton, Amanda Johns, Roderick Alan Porter